Savara (SVRA) Non Operating Income (2017 - 2026)
Savara's (SVRA) quarterly Non Operating Income came in at $1.1 million in Q1 2026, down 29.44% year-on-year from $1.5 million in Q1 2025, and down 11.55% on a QoQ basis from $1.2 million in Q4 2025.
Savara (SVRA) Non Operating Income (2017 - 2026) Analysis & Trends
Savara (SVRA) has 10 years of Non Operating Income data on file, last reported at $1.1 million in Q1 2026.
- On a quarterly basis, Non Operating Income fell 29.44% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 43.72% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 35.64% from the prior year.
- Non Operating Income for Q1 2026 stood at $1.1 million, down from $1.2 million in the prior quarter.
- Over the last five years, Non Operating Income for SVRA reached as high as $2.1 million in Q3 2024 and fell as low as -$570000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $943235.3 across 5 years, with a median of $1.1 million in 2026.
- Across the five-year window, Non Operating Income jumped 850.0% in 2023 and sank 74.26% in 2025, its largest moves.
- Year by year, Non Operating Income stood at $614000.0 in 2022, then soared by 147.39% to $1.5 million in 2023, then increased by 25.94% to $1.9 million in 2024, then tumbled by 37.53% to $1.2 million in 2025, then retreated by 11.55% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $548000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 548,000.00 |
| Jun 30, 2025 | 921,000.00 |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 709,000.00 |
| Mar 31, 2023 | 765,000.00 |
| Dec 31, 2022 | 614,000.00 |
| Sep 30, 2022 | 152,000.00 |
| Jun 30, 2022 | -284,000.00 |
| Mar 31, 2022 | -570,000.00 |
| Dec 31, 2021 | -565,000.00 |
| Sep 30, 2021 | -566,000.00 |
| Jun 30, 2021 | -558,000.00 |